Stockscreener 앱 받기
43.78
2.17%
0.93
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
What technical models suggest about Ionis Pharmaceuticals Inc.’s comebackJuly 2025 Analyst Calls & Safe Entry Point Alerts - Newser
How to use Fibonacci retracement on Ionis Pharmaceuticals Inc.July 2025 Final Week & Weekly Top Performers Watchlists - Newser
Vanguard Group Inc. Has $494.30 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals Inc. stock chart pattern explained2025 Fundamental Recap & Risk Controlled Stock Alerts - Newser
Ionis Pharmaceuticals (NASDAQ:IONS) Given “Neutral” Rating at UBS Group - Defense World
Ionis Pharmaceuticals (IONS) – Investment Analysts’ Weekly Ratings Changes - Defense World
UBS Group Reaffirms “Neutral” Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals shares rise 1.16% premarket after UBS raised its price target to $46. - AInvest
Institutional scanner results for Ionis Pharmaceuticals Inc.Recession Risk & Low Risk Entry Point Tips - Newser
Stocks Flashing Renewed Technical Strength: Ionis Pharmaceuticals - Investor's Business Daily
Ionis Pharmaceuticals Inc. Hits Price Floor — Bounce IncomingLow Capital High Return Stock Plans Reviewed - 선데이타임즈
UBS Reiterates Hold Rating for Ionis Pharmaceuticals with $46 Price Target - AInvest
Ionis Pharmaceuticals Gets Neutral Rating from UBS with $46 Price Target - AInvest
Ionis Pharmaceuticals (IONS) Analyst Rating Update by UBS | IONS Stock News - GuruFocus
Ionis Pharmaceuticals: UBS Raises PT to $46, Maintains Neutral Rating - AInvest
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More - BioSpace
Trend analysis for Ionis Pharmaceuticals Inc. this weekSmart Trade Mapping with Entry Details - Newser
Will Ionis Pharmaceuticals' (IONS) Return to Profitability and Raised Guidance Shift Its Investment Narrative? - simplywall.st
Q3 EPS Estimate for Ionis Pharmaceuticals Reduced by Analyst - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Envestnet Asset Management Inc. - Defense World
Insider Transactions Reported | Ionis Pharmaceuticals(IONS)saw insider trading activity on 8/6/2025 - AInvest
Ionis Pharmaceuticals EVP Geary Richard S sells 10,000 shares at $42.86/share on August 5. - AInvest
S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas - insights.citeline.com
Ionis Pharmaceuticals Inc. stock momentum explainedWeekly Hot Stocks Based on Volume Flow - Newser
Ionis Pharma EVP Schneider sells $408,701 in stock By Investing.com - Investing.com South Africa
Hereditary Transthyretin Amyloidosis (hATTR) Pipeline - openPR.com
Ionis Pharmaceuticals Reports Strong Earnings and Growth - TipRanks
Ionis Pharmaceuticals (IONS): Morgan Stanley Upgrade and Future ProspectsNews and Statistics - IndexBox
Ionis Pharmaceuticals Inc. Stock Lags Behind Sector BenchmarksHigh Growth Low Risk Stock Selection Gets Analyst Nod - beatles.ru
Why Morgan Stanley Upgraded This Biotech Stock to a Buy - Yahoo Finance
Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency - MSN
What analysts say about Ionis Pharmaceuticals Inc. stockBreakout profit opportunities - Jammu Links News
How does Ionis Pharmaceuticals Inc. compare to its industry peersGet exclusive access to expert stock recommendations - Jammu Links News
What are Ionis Pharmaceuticals Inc. company’s key revenue driversFree Popular Stock Recommendations - Jammu Links News
What institutional investors are buying Ionis Pharmaceuticals Inc. stockCapitalize on market momentum for maximum gains - Jammu Links News
Ionis Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Is it the right time to buy Ionis Pharmaceuticals Inc. stockBuild wealth steadily with proven investment techniques - Jammu Links News
Why is Ionis Pharmaceuticals Inc. stock attracting strong analyst attentionAchieve breakthrough profits with expert advice - Jammu Links News
Is Ionis Pharmaceuticals Inc. a growth stock or a value stockMarket-crushing profits - Jammu Links News
Ionis raises 2025 revenue guidance to $850M with Tryngolza momentum and Donidalorsen launch on track - MSN
How volatile is Ionis Pharmaceuticals Inc. stock compared to the marketCapital growth strategies that work - Jammu Links News
What makes Ionis Pharmaceuticals Inc. stock price move sharplyBuild wealth with high-performing stocks - Jammu Links News
What are analysts’ price targets for Ionis Pharmaceuticals Inc. in the next 12 monthsBreakthrough financial growth - Jammu Links News
Ionis Pharmaceuticals (NASDAQ:IONS) Earns “Buy” Rating from HC Wainwright - Defense World
What is Ionis Pharmaceuticals Inc. company’s growth strategyUnprecedented profits - Jammu Links News
What catalysts could drive Ionis Pharmaceuticals Inc. stock higher in 2025Invest confidently with professional advice - Jammu Links News
When is Ionis Pharmaceuticals Inc. stock expected to show significant growthBuild a winning portfolio with smart picks - Jammu Links News
Is Ionis Pharmaceuticals Inc. stock overvalued or undervaluedUnlock powerful market insights for success - Jammu Links News
HC Wainwright Reiterates “Buy” Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals Inc. Stock Analysis and ForecastGet professional advice for portfolio optimization - Jammu Links News
What are the latest earnings results for Ionis Pharmaceuticals Inc.Maximize gains with data-driven trading alerts - Jammu Links News
Cwm LLC Buys 384 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Mixed Analyst Opinions on Healthcare Stocks: Teladoc, Ionis Pharmaceuticals, and Repligen - AInvest
Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) - simplywall.st
How does Ionis Pharmaceuticals Inc. generate profit in a changing economyAI Powered Target Finder For Consistent Profits - Jammu Links News
Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook - MSN
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2025 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
0.41%
0.88%
자본화:
|
볼륨(24시간):